Pfizer completed acquisition of Metsera in November 2025, signaling a major integration effort.

{
  "signal_id": "29c8e4d5-9fff-42d7-b4e8-a011fd821380",
  "signal_type": "sec-10k",
  "signal_subtype": "acquisitionCompleted",
  "detected_at": "2026-03-03T05:50:18.893+00:00",
  "company": {
    "name": "Pfizer",
    "domain": "pfizer.com"
  },
  "data": {
    "detail": "The recent acquisition of Metsera requires the integration of business processes, data, and technology systems. This often creates short-term needs for consulting, IT services, and platform consolidation to realize the transaction's value, particularly in the obesity and cardiometabolic therapeutic areas.",
    "metrics": {
      "timeframe": "current_year"
    },
    "summary": "Pfizer completed acquisition of Metsera in November 2025, signaling a major integration effort.",
    "excerpts": "For a discussion of our strategy and our business development initiatives, including our acquisitions of Metsera in November 2025 and Seagen in December 2023 and our in-licensing agreements with YaoPharma and 3SBio entered into in 2025 in the obesity and cardiometabolic diseases and oncology therapeutic areas, see the Overview of Our Performance, Operating Environment, Strategy and Outlook section within MD&A and Note 2.",
    "relevance": 0.9,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/pfe-20251231.htm",
    "filing_date": "2026-02-26",
    "filing_year": 2026,
    "fiscal_year_end": "12/31",
    "sales_relevance": "Active integration needs",
    "signal_category": "strategic"
  }
}

curl https://signals.autobound.ai/v1/signals/29c8e4d5-9fff-42d7-b4e8-a011fd821380 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"pfizer.com","limit":20}'